PBM trade group and ten pharmacy benefit managers commit to showing TrumpRx cash prices inside benefit tools

The Pharmaceutical Care Management Association (PCMA) and ten pharmacy benefit managers have pledged to show the cash prices listed on TrumpRx alongside the prices patients would pay under their insurance benefit, using the real-time benefit tools that PBMs already supply to prescribers ^[1]. PCMA described the commitment in an August 20, 2026 blog post, saying the announcement was made the prior week in coordination with the Centers for Medicare & Medicaid Services ^[1].

The exact wording of the pledge is narrow. The PBMs "commit to supporting the goals of transparency and affordability by presenting to patients the cash prices listed on TrumpRx for comparison to the prices under their benefit, through use of PBM real time benefit tools, when consistent with plan coverage and allowed by law" ^[1].

CMS Administrator Dr. Mehmet Oz praised the move. "By making negotiated drug prices available alongside cash prices on TrumpRx, this agreement will give patients greater visibility into how much they're paying and help them find the best possible deal," he said. "That's the kind of transparency we need to boost competition, drive down costs, and deliver better value for American patients" ^[1].

What a real-time benefit tool does

Real-time benefit tools, or RTBTs, are software that a doctor can check while writing a prescription. They show what a patient would pay for a given drug under their plan, and often what similar drugs in the same class would cost ^[1]. Under the new commitment, those tools will also display the TrumpRx cash price for a drug when one is available, next to the cost through a network pharmacy under the patient's plan ^[1].

PCMA framed the change as filling a gap. "Today, viewing costs for prescription drugs outside your pharmacy benefit is uncommon and it can be challenging for patients and doctors to find that information," the group wrote ^[1]. It also acknowledged that cash can sometimes win: "While a patient's cost will often be most affordable through their pharmacy benefit, there are times when it will be lower on TrumpRx" ^[1].

The GLP-1 numbers on TrumpRx

GLP-1 drugs are among the most prominent listings on the government site. TrumpRx advertises the Wegovy pill (oral semaglutide) at $149 a month against a $1,349 list price, the Wegovy pen at $199 a month against the same $1,349, Ozempic at $199 a month against $1,028, and Zepbound (tirzepatide) at $299 a month against $1,087 ^[2]. The site's home page claims more than $700,000,000 saved for Americans ^[2].

Those are cash prices, not insurance prices. What a specific person pays with coverage — a flat copay, coinsurance tied to a list price, or nothing at all once a deductible is met — can be higher or lower than the cash figure, which is the comparison the RTBT change is meant to surface ^[1].

Why it matters for patients

For people taking or considering semaglutide or tirzepatide, the practical effect is that the cash-versus-copay question may show up during the visit instead of after a trip to the pharmacy counter. PCMA said displaying both numbers "saves consumers a step" and lets patients "work with their doctor to choose the one that best meets their needs" ^[1].

There are limits worth noting. The pledge applies "when consistent with plan coverage and allowed by law," so it may not appear in every plan or every situation ^[1]. Paying cash generally means the purchase sits outside the insurance benefit, and the sources do not address whether TrumpRx cash spending counts toward a deductible or out-of-pocket maximum. TrumpRx's own FAQ lists questions such as "Can I use my insurance to buy drugs listed on TrumpRx?" and "Can I get TrumpRx prices at my local pharmacy?", but the answers were not captured in the material reviewed here ^[2].

What happens next

Several details are not yet known from these sources. PCMA's post does not name the ten participating PBMs, give a date when TrumpRx prices will start appearing in real-time benefit tools, or say whether the display will reach patient-facing portals and apps as well as prescriber screens ^[1]. PCMA noted the commitment builds on existing PBM investments in online portals, mobile apps and other digital tools that deliver real-time cost information ^[1]. Whether the side-by-side display changes what people actually pay for GLP-1s will depend on how each plan's benefit price compares with the posted TrumpRx price at the time of the prescription ^[1][2].